Brief: UCB Presents New Bimzelx Data At AAD

UCB SA

27/03/2026 14:49

March 27 (Reuters) - Ucb SA UCB.BR:

PRESENTS NEW BIMZELX[®] (BIMEKIZUMAB-BKZX) DATA AT AAD

62.6% AND 64.9% OF THOSE RECEIVING BIMEKIZUMAB-BKZX ACHIEVED NPF-DEFINED ON-TREATMENT REMISSION FOR AT LEAST SIX MONTHS IN FIRST YEAR

THOSE WHO RELAPSED AFTER STOPPING TREATMENT, 83.6% ACHIEVED PASI100 AT FOUR YEARS AFTER BEING RETREATED WITH BIMEKIZUMAB-BKZX

Source text: [https://tinyurl.com/27pjo6zg]

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))